acute myeloid leukaemia (AML)

article

SEL120: a promising CDK8 kinase inhibitor

28 October 2019 | By Victoria Rees (Drug Target Review)

A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.

news

Study identifies molecule key in leukaemia treatment resistance

28 August 2019 | By Victoria Rees (Drug Target Review)

Researchers have found a molecule, which when deleted, increases leukaemia sensitivity to natural killer cells and is a drug target.

news

Epigenetic protein could be new therapeutic target in acute myeloid leukemia

19 March 2019 | By Drug Target Review

The epigenetic protein, EZH2, was found to delay the development of acute myeloid leukemia (AML) but also switches sides to maintain tumour growth...

news

Tailoring treatment for acute myeloid leukaemia

10 December 2018 | By Drug Target Review

Rapid drug response screening for leukaemia stem cells offers clues to relapse and to improving patient-specific therapies...

news

CRISPR approach could limit toxicity of CAR-T therapy in AML

4 June 2018 | By Dr Zara Kassam (Drug Target Review)

New study uses CRISPR/Cas9 to make CD33 CAR T cells cancer-specific...

news

IL1RAP protein boosts multiple oncogenic pathways in AML

18 May 2018 | By Dr Zara Kassam (Drug Target Review)

Researchers have discovered that a signalling protein elevated in patients with AML plays a much wider role in the disease than previously thought...